Shares

11 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 13, 2024

BUY
$1.25 - $2.51 $3,433 - $6,894
2,747 Added 67.58%
6,812 $9,000
Q3 2023

Nov 14, 2023

SELL
$2.15 - $3.59 $3,753 - $6,268
-1,746 Reduced 30.05%
4,065 $9,000
Q2 2023

Aug 14, 2023

BUY
$2.52 - $4.0 $9,530 - $15,128
3,782 Added 186.4%
5,811 $19,000
Q1 2023

May 09, 2023

BUY
$2.66 - $4.36 $2,761 - $4,525
1,038 Added 104.74%
2,029 $5,000
Q4 2022

Feb 10, 2023

SELL
$2.81 - $39.7 $1,199 - $16,951
-427 Reduced 30.11%
991 $3,000
Q3 2022

Nov 10, 2022

BUY
$3.97 - $42.7 $3,124 - $33,604
787 Added 124.72%
1,418 $5,000
Q2 2022

Aug 15, 2022

BUY
$5.93 - $15.61 $3,741 - $9,849
631 New
631 $4,000
Q1 2022

May 12, 2022

SELL
$5.06 - $13.8 $17,816 - $48,589
-3,521 Closed
0 $0
Q4 2021

Feb 14, 2022

BUY
$2.92 - $42.3 $10,281 - $148,938
3,521 New
3,521 $42,000
Q2 2021

Aug 16, 2021

SELL
$5.2 - $8.13 $25,355 - $39,641
-4,876 Closed
0 $0
Q1 2021

May 17, 2021

BUY
$5.66 - $8.45 $27,598 - $41,202
4,876 New
4,876 $32,000

Others Institutions Holding LGVN

About Longeveron Inc.


  • Ticker LGVN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 5,925,940
  • Market Cap $10.5M
  • Description
  • Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult ...
More about LGVN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.